The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.